These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21269572)

  • 1. Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis.
    Besada E; Nikolaisen C; Nossent H
    Clin Exp Rheumatol; 2011; 29(1):85-8. PubMed ID: 21269572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
    Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
    Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
    Damjanovska L; Thabet MM; Levarth EW; Stoeken-Rijsbergen G; van der Voort EI; Toes RE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2010 Apr; 69(4):730-2. PubMed ID: 19451136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
    Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis.
    Al-Jarallah K; Shehab D; Al-Attiyah R; Al-Azmi W; Al-Fadli A; Zafar Haider M; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1655-62. PubMed ID: 22114016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
    Nicaise Roland P; Grootenboer Mignot S; Bruns A; Hurtado M; Palazzo E; Hayem G; Dieudé P; Meyer O; Chollet Martin S
    Arthritis Res Ther; 2008; 10(6):R142. PubMed ID: 19077182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios.
    Pietrapertosa D; Tolusso B; Gremese E; Papalia MC; Bosello SL; Peluso G; Petricca L; Michelutti A; Faustini F; Fedele AL; Ferraccioli G
    Clin Chem Lab Med; 2010 Jun; 48(6):829-34. PubMed ID: 20298138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis.
    Mutlu N; Bicakcigil M; Tasan DA; Kaya A; Yavuz S; Ozden AI
    J Rheumatol; 2009 Mar; 36(3):491-500. PubMed ID: 19228660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.